Skip to main content
. 2019 Jan 21;11(1):124. doi: 10.3390/cancers11010124

Figure 2.

Figure 2

Progression-free survival (PFS) of patients with metastatic anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) under treatment with tyrosine kinase inhibitors (TKI) according to TP53 status at baseline and progression. (A) The median time-to-next-treatment (TNT) under TKI for patients with initially wild-type TP53 tumours after reassessment of TP53 status was 9 months for cases with a positive result (TP53mutconv) vs. 23 months for cases with negative result (TP53wtprogr, logrank p = 0.0013). Treatment details including continuation of treatment beyond disease progression are given in Table 1. (B) The median PFS under TKI treatment across all treatment lines was 8 months for patients with TP53 mutations at baseline (TP53mutbas) vs. 5 months for patients with initially wild-type status and detection of TP53 mutations in a subsequent biopsy (TP53mutconv) vs. 13 months for patients without subsequent detection of TP53 mutations (TP53wtprogr, logrank p = 0.0039); ns: not significant.